BioLineRx (BLRX) Intangibles (2011 - 2025)

BioLineRx's Intangibles history runs 15 years deep, the most recent figure standing at $16.4 million for Q4 2025.

• On a quarterly basis, Intangibles rose 56.65% year-over-year to $16.4 million in Q4 2025; TTM through Dec 2025 was $16.4 million, a 56.65% increase from a year earlier, with the FY2025 full-year figure at $16.4 million, up 56.65% from the prior year.
• Intangibles rose to $16.4 million in Q4 2025 per BLRX's latest filing, from $10.4 million in the prior quarter.
• Across five years, Intangibles topped out at $22.0 million in Q3 2023 and bottomed at -$671000.0 in Q4 2023.
• The 5-year median for Intangibles is $21.7 million (2021), against an average of $16.7 million.
• Biggest YoY gain for Intangibles was 1657.23% in 2024; the steepest drop was 39.86% in 2024.
• Year by year, Intangibles stood at $21.7 million in 2021, then climbed by 0.06% to $21.7 million in 2022, then tumbled by 103.09% to -$671000.0 in 2023, then surged by 1657.23% to $10.4 million in 2024, then soared by 56.65% to $16.4 million in 2025.
• Per Business Quant, the three latest BLRX Intangibles figures stand at $16.4 million (Q4 2025), $10.4 million (Q3 2025), and $10.4 million (Q2 2025).